Clinical trials: Cancer, Advanced
Fatigue
PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care
The objective of this study is to conduct a trial in the spirit of providing as much as possible the benefit of PG2 treatment to eligible patients and to evaluate the efficacy and safety of PG2 for relieving fatigue among…
- Trial name
- NCT00523107
- Testing
- PG2
- Where
- Taiwan
- Volunteers
- 91 people
- Sponsor
- PhytoHealth Corporation
Thyroid Cancer
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.
- Trial name
- NCT04309136
- Testing
- Anlotinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Fudan University
Efficacy, Toxicity
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy.
- Trial name
- NCT03491371
- Testing
- Methylsulfonic apatinib
- Where
- 2 sites in China
- Volunteers
- 56 people
- Sponsor
- Peking University People's Hospital
Gastrointestinal Stromal Tumor, Sarcoma
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally…
- Trial name
- NCT00041249
- Testing
- brostallicin
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, Acute Leukemia
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma
- Trial name
- NCT01499147
- Testing
- fludarabine/busulfan, fludarabine/ melphalan, ATG
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois Chicago
Solid Tumors
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors
- Trial name
- NCT04685226
- Testing
- ICP-723
- Where
- 24 sites in China
- Volunteers
- 310 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Gastric Cancer
Surgery for Obstructed Gastric Carcinoma
The goal of this clinical trial is to find the best treatment for obstructed gastric carcinoma in gastric cancer patients. It will include all patients with obstructed gastric cancer with different ages and sex who consented to…
- Trial name
- NCT07435025
- Testing
- palliative gastric resection, palliative bypass
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- Zagazig University
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Trial name
- NCT02711345
- Testing
- LTT462
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma (GBM)
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN
Patients will receive in addition to standard histology analysis also the PDC- based drug screening.
- Trial name
- ATTRACTION (NCT07627334)
- Testing
- CBmed drug screening platform
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Non-Small Cell Lung Cancer
An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).
This is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of EGFR mutations in treatment-naive Russian patients with…
- Trial name
- ORTUS (NCT02321046)
- Where
- 26 sites in Russia
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Recurrent Renal Cell Cancer, Renal Cell Carcinoma
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic…
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00684996
- Testing
- etaracizumab, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer, Radiation Toxicity
Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concurrent…
- Trial name
- RICT-LUNG (NCT03416972)
- Testing
- Standard platinum-based chemoradiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Hodgkin's Disease
Allogeneic Blood Stem Cell Transplantation
1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem cell transplantation after intensive but non-myeloablative chemotherapy in patients with relapsed Hodgkin's disease (HD). 2.
- Trial name
- NCT00423709
- Testing
- Allogeneic Blood Stem Cell Transplantation, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoid Neoplasm
Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma
Although modern radiation techniques combined with chemotherapy has greatly improved the local control and long-term survivals for patients with early-stage NKTCL, relapse and systemic dissemination are common for localized…
- Trial name
- NCT04509804
- Testing
- non-interventional
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Chinese Academy of Medical Sciences
Osteosarcoma, Neuroblastoma
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
Cd276 (B7-H3) is an ideal target for car-t treatment because of its high expression on the surface of neuroblastoma, osteosarcoma, gastric cancer and lung cancer cells, but not in normal peripheral cells or tissues.
- Conditions
- Osteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer
- Trial name
- NCT04864821
- Testing
- Targeting CD276 CAR T cells
- Volunteers
- 24 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Non-Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer Stage IV
Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
This study is an observational study evaluating the treatment patterns and clinical outcomes after progression on first-line Tislelizumab treatment in advanced NSCLC.
- Trial name
- REALM-Post (NCT06962449)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Sarcoma
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
Monocentric, phase I study for advanced sarcoma with adoptive immunotherapy with Cytokine-Induced Killer (CIK). In the first part of the study Patient's' peripheral blood will be collected and CIK cell expansion and storage will…
- Trial name
- CAST (NCT03782363)
- Testing
- Autologous CIK Dose level 1, Autologous CIK Dose level 2, Autologous CIK Dose level 3
- Where
- Italy
- Sponsor
- Italian Sarcoma Group
Advanced Cancers and FGFR Genetic Alterations
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options
The purpose of this program is to provide participants an early access to erdafitinib prior to market authorization (that is, Food and Drug Administration [FDA] approval in the United States).
- Trial name
- NCT03825484
- Testing
- Erdafitinib
- Sponsor
- Janssen Scientific Affairs, LLC
Advanced Cancers
The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients
Cachectic patients often lose their appetite, lose weight, and are prone to weakness and even death in advanced illness. Nutrition therapy is important and of concern to the investigators in cancer patients.
- Trial name
- NCT00208013
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- China Medical University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.